Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax
Meng Zhang, Xiao Chai, Xiaomei Zhang, Wenyi Lu, Hairong Lyu, Yedi Pu, Juanxia Meng, Cuicui Lyu, Mingfeng Zhao · 2026
Read Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax by Meng Zhang, Xiao Chai, Xiaomei Zhang, Wenyi Lu, Hairong Lyu, Yedi Pu, Juanxia Meng, Cuicui Lyu, Mingfeng Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13481568.txt.
Description
Meng Zhang and eight co-authors test engineered immune cells against blood cancers carrying a certain marker, in a paper dated 2026. The therapy, CAR-T, retools a patient's own T cells to hunt cancer. It shines in lymphoid cancers but has disappointed in myeloid ones, the target here.
Fifteen patients with myeloid tumors received cells aimed at the CD123 marker. Results were weak: a few reached deep remission, most did not. The team then asked whether a cancer drug, venetoclax, could sharpen the cells. In dishes, modest doses left the CAR-T cells unharmed while stressing cancer cells, and pairing raised killing and signal output. Pre-treating the cells with the drug is explored as the next step. The paper is candid that this target needs help to work.
Catalog record
| CREATOR | Meng Zhang, Xiao Chai, Xiaomei Zhang, Wenyi Lu, Hairong Lyu, Yedi Pu, Juanxia Meng, Cuicui Lyu, Mingfeng Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |